Welcome to our dedicated page for Ionis Pharmaceuticals news (Ticker: IONS), a resource for investors and traders seeking the latest updates and insights on Ionis Pharmaceuticals stock.
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) is a leading biotechnology company headquartered in Carlsbad, California. Founded in 1989, Ionis has been pioneering the discovery and development of antisense drugs, with an impressive portfolio of over 1300 patents. Ionis focuses on creating innovative RNA-targeted therapies for complex diseases, particularly in the areas of cardiovascular, metabolic, neurological, and rare genetic disorders.
Ionis has successfully brought several groundbreaking medicines to market. Notable achievements include the development of Spinraza, in collaboration with Biogen, which was launched in 2016 to treat spinal muscular atrophy, a rare neuromuscular disorder. In 2023, Biogen also launched Qalsody for ALS, further extending the impact of Ionis' antisense technology.
Through its cardiovascular-focused subsidiary, Akcea Therapeutics, Ionis has introduced drugs like Tegsedi for ATTR amyloidosis and Waylivra in Europe for cardiology indications. The company continues to advance its pipeline with promising candidates such as olezarsen, an investigational RNA-targeted therapy for familial chylomicronemia syndrome (FCS). Ionis' ongoing Phase 3 trials for olezarsen have shown promising results, with significant reductions in triglyceride levels and improvements in related health outcomes.
Ionis' commitment to innovation and patient care is also evident in its robust financial health and strategic partnerships. With a deep understanding of disease biology and cutting-edge technology, Ionis continues to drive advancements in RNA therapies and gene editing, aiming to deliver life-changing medicines for patients around the world.
Recently, Ionis announced positive clinical trial results for several of its investigational drugs and plans to pursue regulatory approvals for these therapies. The company's pipeline is well-positioned to address unmet medical needs in various therapeutic areas, promising a steady flow of new treatments in the coming years.
For more detailed information about Ionis Pharmaceuticals, its products, and career opportunities, visit their official website at www.ionispharma.com.
Ionis Pharmaceuticals (NASDAQ: IONS) has successfully completed enrollment in its pivotal Phase 3 NEURO-TTRansform study, exceeding its target with over 160 patients participating. The study focuses on eplontersen for treating hereditary transthyretin-mediated amyloid polyneuropathy (hATTR-PN). Eplontersen, an investigational drug using Ionis' LICA technology, showed up to 94% reductions in transthyretin (TTR) in Phase 1 trials. An interim analysis is expected by mid-2022, with a potential NDA filing by year-end 2022.
Biogen and Ionis Pharmaceuticals reported positive topline data from a Phase 1b clinical trial of BIIB080, aimed at treating mild Alzheimer's disease. The trial demonstrated significant dose-dependent reductions in tau protein levels in cerebrospinal fluid, achieving mean reductions of 30% to 49% across various dosing schedules. All participants completed the treatment phases, with no serious adverse events reported. These findings underscore the potential of BIIB080 and Ionis' antisense technology in addressing neurodegenerative diseases, paving the way for further clinical investigations.
Ionis Pharmaceuticals (NASDAQ: IONS) announced a live webcast scheduled for August 4, 2021, at 11:30 a.m. ET, to discuss its Q2 2021 financial results along with updates on its pipeline and business progress. Ionis has been a leader in RNA-targeted therapy for over 30 years, with three marketed medicines and a strong late-stage pipeline. The webcast will be accessible via their investor relations page, and a replay will be available for a limited time.
Ionis Pharmaceuticals has entered an exclusive licensing agreement with Bicycle Therapeutics to enhance its LIgand Conjugated Antisense (LICA) medicines. The deal grants Ionis access to Bicycle's proprietary Bicycles, targeting transferrin receptor 1 to improve delivery of oligonucleotides. Ionis made a $45 million upfront payment, which includes a license fee and equity investment. This partnership aims to boost Ionis' drug discovery capabilities, potentially leading to better treatment options for patients.
Ionis Pharmaceuticals announced that Executive VP and CSO C. Frank Bennett has received the 23rd Jacob and Louise Gabbay Award for his contributions to antisense therapy. The award honors significant advances in biomedical sciences and includes a cash prize and medallion. Bennett shares the recognition with Adrian R. Krainer and is acknowledged for his pivotal role in developing SPINRAZA, the key treatment for spinal muscular atrophy. He is a founding member of Ionis and has received several prestigious awards for his ongoing research in RNA-targeted therapies.
Ionis Pharmaceuticals (NASDAQ: IONS) announced the presentation of its advances in ATTR amyloidosis therapies at the 2021 Peripheral Nerve Society Annual Meeting, scheduled for June 12-13 and 25-27. The company highlights its commitment to innovating antisense therapies for this condition. Key presentations include a plenary lecture by Dr. Frank Bennett and a panel discussion moderated by Dr. Kemi Olugemo. Additionally, multiple on-demand posters will address various aspects of TTR amyloidosis treatment, showcasing Ionis' ongoing research and development efforts in the field.
Ionis Pharmaceuticals has announced significant leadership changes in its board of directors. Joseph Loscalzo, M.D., Ph.D., has been appointed chairman, succeeding Stanley Crooke, who has retired but will remain as a scientific advisor. Allene M. Diaz has also joined the board. Dr. Loscalzo's background includes extensive experience at Harvard Medical School and numerous accolades in cardiovascular science. Diaz brings a wealth of experience from her previous roles in GlaxoSmithKline and other firms. These changes aim to bolster Ionis's strategy towards delivering over 12 novel RNA-targeted therapies by 2026.
Ionis Pharmaceuticals (Nasdaq: IONS) will present a company overview at several upcoming virtual investor conferences. Key dates include:
- June 1, 2021: William Blair 41st Annual Growth Stock Conference
- June 9, 2021: Goldman Sachs 42nd Annual Global Healthcare Conference
- June 15, 2021: Nasdaq 44th Investor Conference
- June 22, 2021: BMO Biopharma Day: Spotlight on Rare Disease and Ophthalmology
Live webcasts will be available on Ionis' website, with replays archived for a limited time.
Ionis Pharmaceuticals (Nasdaq: IONS) announced participation in virtual fireside chats at two major investor conferences. The Bank of America Healthcare Conference is scheduled for May 12, 2021, and the RBC Capital Markets Global Healthcare Conference on May 19, 2021. The company will provide updates on presentation times and changes via its website. Live webcasts will be accessible in the Investors & Media section, with replays available within 48 hours. Ionis is recognized for its leadership in RNA-targeted therapy and has three marketed medicines.
Ionis Pharmaceuticals (Nasdaq: IONS) announced its 2021 virtual Annual Meeting of Stockholders will take place on June 2, 2021, at 5:00 p.m. ET. All stockholders of record as of April 5, 2021, are invited to participate via a live webcast. The meeting will include a corporate update presented by CEO Brett P. Monia at 5:30 p.m. ET. Participants must have a 16-digit control number to join the meeting. Links for participation and further details are available on their website.
FAQ
What is the current stock price of Ionis Pharmaceuticals (IONS)?
What is the market cap of Ionis Pharmaceuticals (IONS)?
What does Ionis Pharmaceuticals specialize in?
Where is Ionis Pharmaceuticals located?
What are some key products developed by Ionis Pharmaceuticals?
What is the latest development in Ionis' pipeline?
Who are some of Ionis' key partners?
How does Ionis Pharmaceuticals contribute to RNA therapy innovation?
What is olezarsen and what does it treat?
How can I learn more about career opportunities at Ionis Pharmaceuticals?
What recent clinical trials has Ionis Pharmaceuticals announced?
How does Ionis Pharmaceuticals support patients with rare diseases?
